Table 3.
Comparison of Clinical Characteristics Between 30-Day Survivors and Non-Survivors with CRPA Infection
| Characteristics | Total (n=136) | Survivors (n=89) | Non-Survivors (n=47) | P value |
|---|---|---|---|---|
| Demographic variables | ||||
| Male sex | 100 (73.5) | 67 (75.3) | 33 (70.2) | 0.524 |
| Age (years) | 61.5 (51.25–70) | 62 (50.5–70.0) | 61 (53–71) | 0.980 |
| BMI | 23.55±4.47 | 23.76±4.67 | 23.15±4.10 | 0.446 |
| CCI | 3 (2–4) | 3 (1–4) | 3 (3–4) | 0.015 |
| aCCI | 4 (3–6) | 4 (3–6) | 5 (4–6) | 0.045 |
| APACHE II score | 16 (12–22) | 16 (12–20) | 17 (12–23) | 0.277 |
| SOFA score | 6 (4–8) | 6 (4–8) | 7 (4–9) | 0.338 |
| Comorbidities | ||||
| Cardiovascular disease | 46 (33.8) | 33 (37.1) | 13 (27.7) | 0.270 |
| Chronic pulmonary disease | 35 (25.7) | 30 (33.7) | 5 (10.6) | 0.003 |
| Chronic kidney disease | 7 (5.1) | 5 (5.6) | 2 (4.3) | 1 |
| Chronic liver disease | 9 (6.6) | 7 (7.9) | 2 (4.3) | 0.658 |
| Cerebrovascular disease | 39 (28.7) | 23 (25.8) | 16 (34.0) | 0.315 |
| Gastrointestinal diseases | 15 (11.0) | 10 (11.2) | 5 (10.6) | 0.916 |
| Hypertension | 57 (41.9) | 38 (42.7) | 19 (40.4) | 0.799 |
| Diabetes mellitus | 32 (23.5) | 19 (21.3) | 13 (27.7) | 0.409 |
| Solid tumor | 16 (11.8) | 9 (10.1) | 7 (14.9) | 0.411 |
| Hematologic malignancy | 2 (1.5) | 1 (1.1) | 1 (2.1) | 1 |
| Organ transplant | 27 (19.9) | 23 (25.8) | 4 (8.5) | 0.016 |
| Chemotherapy | 2 (1.5) | 1 (1.1) | 1 (2.1) | 1 |
| Immunosuppressants use | 32 (23.5) | 23 (25.8) | 9 (19.1) | 0.381 |
| Corticosteroid use | 58 (42.6) | 37 (41.6) | 21 (44.7) | 0.727 |
| Surgical history | 101 (74.3) | 73 (82.0) | 28 (59.6) | 0.004 |
| Invasive procedures | ||||
| Endotracheal intubation | 122 (89.7) | 78 (87.6) | 44 (93.6) | 0.427 |
| Tracheotomy | 81 (59.6) | 60 (67.4) | 21 (44.7) | 0. 010 |
| Mechanical ventilation | 136 (100) | 89 (100) | 47 (100) | 1 |
| Central venous catheter | 118 (86.8) | 77 (86.5) | 41 (87.2) | 0.907 |
| CRRT | 66 (48.5) | 30 (33.7) | 36 (76.6) | <0.001 |
| Septic shock | 57 (41.9) | 25 (28.1) | 32 (68.1) | <0.001 |
| Infection variables | ||||
| Pulmonary infection | 135 (99.3) | 88 (98.9) | 47 (100.0) | 1 |
| Bloodstream infection | 49 (36.0) | 28 (31.5) | 21 (44.7) | 0.127 |
| Intra-abdominal infection | 4 (2.9) | 2 (2.2) | 2 (4.3) | 0.900 |
| Other infection sites | 29 (21.3) | 24 (27.0) | 5 (10.6) | 0.027 |
| Treatment variables | ||||
| Duration of therapy | 9 (5–14) | 11 (7–17) | 6 (4–9) | <0.001 |
| Time to initiation of treatment | 6.5 (4–12.75) | 6 (4–15) | 7 (3–10) | 0.348 |
| CAZ/AVI use | 51 (37.5%) | 44 (49.4) | 7 (14.9) | <0.001 |
| Polymyxin B use | 85 (62.5%) | 45 (50.6) | 40 (85.1) | <0.001 |
| Outcomes | ||||
| The length of ICU (days) | 28 (17–44.5) | 34.09 (24.5–58) | 18 (13–25) | <0.001 |
| The length of hospitals (days) | 34 (22.67–61) | 46 (30–78.5) | 21 (15–33) | <0.001 |
| Bacterial eradication | 34 (25.0) | 34 (38.2) | 0 (0) | <0.001 |
Notes: Data are expressed as number (%) or mean± SD or median (IQR).
Abbreviations: BMI, Body mass index; CCI, Charlson comorbidity index; aCCI, age-adjusted Charlson comorbidity index; CRRT, Continuous renal replacement therapy; ICU, Intensive care unit; IQR, Interquartile range.